Novo Nordisk to invest 8.5 billion Danish kroner (€1.14B) in new production facility in Denmark.

Novo Nordisk announced Monday it plans to invest 8.5 billion Danish kroner (€1.14B) to establish a completely new production facility in Odense, Denmark. The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site, the company said in a press release.

The new site will feature a state-of-the-art finished production facility and warehouse spanning over 40,000 m². Designed to be modular and flexible, it will accommodate multiple product types within rare disease, such as haemophilia, both now and in the future.

Henrik Wulff, executive vice president, Product Supply, Quality & IT of Novo Nordisk, said: “The facility will utilise advanced technology and innovative equipment to ensure the highest quality to patients and meet the growing global demand for our life-changing medicines. We are proud to build on our heritage in Denmark and look forward to embarking on this journey in Odense, a well-connected city with a dynamic community and talented workforce.”

According to Novo Nordisk, the new facility will be established with a commitment to preserve the nature in the area, and more than 4,000 new trees will be planted at the site. Buildings will be equipped with solar panels to enhance on-site electricity generation. The landscape will be designed by reusing excess soil, wooden materials and other sustainable resources to create lakes, forests and community spaces open to the public, the company said in a press release.
Novo Nordisk said that the construction work has started and is scheduled to be completed in 2027. The investment is expected to create 400 permanent jobs upon completion of the facilities. During the construction process, up to 1,000 external employees will be working on-site, the company said.